VIDEO: Expert discusses findings from Impower010 study
Nathan A. Pennell, MD, PhD, medical oncologist at the Cleveland Clinic and associate professor of medical oncology at the Cleveland Clinic Lerner College, spoke with Healio about exciting presentations in lung cancer from the virtual ASCO Annual Meeting.
“The most talked about abstract, and what I certainly found most interesting from the ASCO 2021 lung session, was in the adjuvant setting actually,” he said.
According to Pennell, the study design included an interesting endpoint that first targeted patients with PDL-1 expression before the entire intent-to-treat population. The patients with PDL-1 biomarkers demonstrated “statistically significant” disease free survival.
“This is more likely to translate to an overall survival benefit because of how durable and effective immune therapy is,” Pennell said.
Collapse
Healio Interview; Wakelee HA, et al. Abstract 8500. Scheduled for presentation at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about